Isavuconazole
Invasive aspergillosis and mucormycosis (deep fungal infections)
- CAS No.
- 241479-67-4
- Indication Class
- Anti-infectives
- Patent Expiry
- Expiring within 2 yrs · 2027 (indicative)
- Therapeutic Area
- Antifungal
- Labeled Purity
- 99%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
- Patent Scope
- US / EU compound patent
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
A broad-spectrum triazole covering both aspergillus and mucor, for critical deep fungal infections in immunocompromised patients, an ICU/hematology must-have replacing amphotericin B.
Antifungal · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Isavuconazole is a broad-spectrum triazole antifungal medication, approved by the FDA and EMA. It is indicated for the treatment of serious invasive fungal infections, primarily invasive aspergillosis and mucormycosis, in adult patients.
Supply source: Unibest · Isavuconazole, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.